The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
about
New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α)Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.Protection from Cigarette Smoke-Induced Lung Dysfunction and Damage by H2 Relaxin (Serelaxin).Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies.
P2860
The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The emerging role of relaxin a ...... ent of chronic kidney disease.
@en
The emerging role of relaxin a ...... ent of chronic kidney disease.
@nl
type
label
The emerging role of relaxin a ...... ent of chronic kidney disease.
@en
The emerging role of relaxin a ...... ent of chronic kidney disease.
@nl
prefLabel
The emerging role of relaxin a ...... ent of chronic kidney disease.
@en
The emerging role of relaxin a ...... ent of chronic kidney disease.
@nl
P2860
P1476
The emerging role of relaxin a ...... ent of chronic kidney disease.
@en
P2860
P304
P356
10.1152/AJPREGU.00528.2012
P577
2013-07-24T00:00:00Z